Disuptive treatments for unresolved inflammation and pain
The therapeutics industry is evolving at an unprecedented pace, fueled by cutting-edge science and innovative technologies. Despite advancements, there are still many chronic conditions that lack effective treatments, including those involving unresolved inflammation. These conditions, often unresponsive to traditional anti-inflammatory therapies, urgently require improved treatment options. That’s why we are harnessing the power of maresin compounds to support inflammation resolution for difficult-to-treat inflammatory diseases.
Discover how we are accelerating the route towards the first drug for localized provoked vulvodynia (LPV), a highly debilitating condition affecting more than 16% of women in their lifetime. With extensive preclinical evidence demonstrating the efficacy and safety of our maresin-derived compounds in significantly improving vulvodynia-related pain, we are now preparing a phase 1/2a clinical trial in women with LPV.
Tell me moreBeyond LPV, we’re pushing the therapeutic potential of maresins to new levels, helping more people lead healthier, happier lives. We have a strong pipeline of programs in diseases characterized by detrimental inflammation and unmet medical needs, such as systemic lupus erythematosus (SLE), inflammatory skin conditions and oncology.
Explore our programs